Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Pxs website updated , at least Our main holders haven’t sold any , https://www.provexis.com/shareholder-information/major-shareholders/
Look on the positive side;At least we still haven't got Moon in charge;doing well again I see @SIS
Two sells so far, guessing that's CB and Nazir out...
It just shows you ,totally agree with the last statement.
Another year ,,what's happened about the blue cap
i ,believed the first half of 2022 we would've got feedback on the last three
A new worry is having to make a decision about buying remaining stock and how to finance it. It's just an endless saga and the company simply cannot make a profit after all these years.
Another empty jam jar. 15 years in this, and the reports always read the same... "Next year Rodders". Another cut and paste from prior year except where they need to provide more info for going concern purposes (or, in other words: please give us more money)
0.70 to buy?
We will see ,i hope you are right
Wait and see. Lots said that before last year's AGM and look what happened. Be happy
Nothing to report ,that's why leave it to the last day ,sp dropping again
Isn't that what most folks have been hoping for?
As I've soliloquied in the past, looks like FF is outgrowing us.
W$
Yes wellsite, its been popping up quite a lot in the internet but its good that it came directly from the By-Health website as we don't get a lot of good info from them.
"The discovery of this new mechanism further unveils the mystery of Qingluoxin" (fruitflow), "and provides more new ideas for its functional transformation and product landing. With the deepening of scientific research, it is expected to bring more health products with scientific and technological content to the public in the future"
May be taking longer than we first thought but the end result should be good.
Nice one gix
being cut and pasted
https://www-pharmnews-com.translate.goog/news/articleView.html?idxno=210755&_x_tr_sl=zh-CN&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
https://cj-sina-com-cn.translate.goog/articles/view/1820447737/6c81d3f9019016i7i?_x_tr_sl=zh-CN&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
W$
I don’t expect anything new in the results,we know revenue and unless By health have completed their 3 remaining studies I think the blue hat will be “progressing well”as usual , as someone has already pointed out revenue from the DSM transfer won’t become clear until after year end 23 . I hope there is some clarity on the huge ramp up in production needed and how it will be payed for .
Yes great work Gixer. Not long now
Great writeup in the Enterprise News section of By-Healths website.
https://www.by-health.com/news-4588
Hi gixer,
As usual many thanks for sharing the great finds. Hope all these will translate in to increased sales.
and they keep popping up.
https://k-sina-com-cn.translate.goog/article_1664221137_6331ffd1020016hyc.html?_x_tr_sch=http&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp#/
https://www-sohu-com.translate.goog/a/587650785_121118802?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp
https://www-163-com.translate.goog/dy/article/HHVKDDD90548OE0Z.html?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp
Chinese articles
The "cardiovascular health guard" in tomato - Qingluosu, the latest research by BY-HEALTH reveals its new mechanism
https://www-sohu-com.translate.goog/a/587331025_100199396?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp
Think this might have been posted before but dated yesterday.
The old articles seem to pop up on a regular basis.
https://www-163-com.translate.goog/dy/article/HHSSAGUS05532JVW.html?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp
DSM patent.
Not read this so not sure why Fruitflow gets a mention in this new patent from DSM.
COMPUTER-BASED METHOD FOR DESIGNING NUTRITIONAL VALUABLE MEAT AND FISH ALTERNATIVES BASED ON NON-ANIMAL PROTEINS, COMPUTER PROGRAM PRODUCT FOR IT, NUTRITIONAL VALUABLE MEAT AND FISH ALTERNATIVES AND THEIR MANUFACTURE
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022194786&_cid=P10-L8E0EB-56467-1
I was thinking Atherosclerosis.
Very keen on getting some info on this as well although it could be a long way off.
At the very least it would be good to know what area the drug would target.
Pure speculation but could it be..........
COMPOSITION WITH EFFECT OF ASSISTING IN REDUCING BLOOD FAT
"?Experimental studies accidentally found that the water-soluble tomato concentrate and the functional red yeast powder have a coordinated synergistic effect in the aspect of assisting in reducing blood fat, and the two are compounded, so that the levels of triglyceride, cholesterol and low-density lipoprotein can be obviously reduced, thereby achieving an excellent effect of assisting in reducing blood fat."
https://patentscope.wipo.int/search/en/detail.jsf?docId=CN362207783&_cid=P10-L8DCEM-22132-1
I missed Development of FF as a Drug. That's one I'm keen on getting updates on.
If anyone has spare time, here is the study regarding the Liverpool Uni work on a new 'Contrabiotic' Non-Starch Polysaccharide and its efficacy against E-Coli, C-Diff etc..
https://www.frontiersin.org/articles/10.3389/fphar.2021.766293/full
That's a fine piece of work, quite comprehensive.
Use of Fruitflow medically would surely be subject to a lot more regulatory work. That seems to have been the case for so many potential benefits, from alleviating symptoms of air particulate pollution onwards. Initial studies look very promising, but lack of ability to throw resources at it tends to mean nothing further happens, only the discovery of yet more potential benefits. We have something here that could better the lives of so many folks, in so many different ways. If only we could crack the first hurdle, and achieve the aim of expansion through self funding.
What we are expecting in the update:
Provexis FF sales update, new customers, global customers, distributors etc.
Factory scale-up to meet higher demand forecast.
FF+ combination products, and it is currently in dialogue with some other potential international direct selling customers.
FF + O3 Chinese distributor progress
FF + Nitrates launch progress
FF+ Subscriber numbers
DSM Progress with commercialisation of FF as a Gut Health ingredient (Hologram Sciences?)
DSM Progress with sales of FF as part of premix solutions
BH progress with the remaining 3 studies and submission to SAMR
Platelet hyperactivity in COVID-19: Can the tomato extract Fruitflow® be used as an antiplatelet regime?
Development of a new ‘contrabiotic’ polysaccharide which show efficacy against pathogens such as E coli, C difficile and S typhimurium.
Chrohn’s disease IP development options
Revenue growth +/-
Current funding situation and future financial forecast